Implementation Challenges

Nirsevimab Payment and Coding Issues

Cheryl De Pinto, MD, MPH, FAAP
Senior Vice President, Primary and Subspecialty Care
American Academy of Pediatrics
AAP Readying for Nirsevimab Roll Out

- New and exciting product comes with significant implementation challenges

- AAP has been working to improve coding and payment for physicians and qualified health providers (QHPs)
Vaccine Administration vs. Injection of Drug or Substance

**Vaccine Admin– 90460**
- Immunization admin, with counseling by physician or qualified health provider (QHP)
- Incorporates costs for practice expense in storage of immunizations and entry into state registry

**Injection Drug/Sub – 96372**
- Used for therapeutic injections
- Does not include the physician or QHP effort in counseling, nor the practice expense in storage of immunizations and entry into the state registry
AAP Proposal for New Passive Immunization Administration Code

- AAP urged the AMA CPT panel to adopt new administration codes for immune globulin products that incorporate counseling and practice expenses.

- The AMA CPT panel considered the AAP proposal for an administration codes specific to nirsevimab.

- We are hopeful the code will be approved.
Need Expedited RUC Valuation of New Codes

- In the event of approval by the CPT panel of a new administration code for nirsevimab, AAP is also urging an expeditious valuation by the RUC that can be effective immediately so it can be used soon given the fast-approaching RSV season.

- The AAP urged the code to be valued at, or above the value for the current immunization administration code.
Thank You!